Consumer medicine information

Androforte 5

Testosterone

BRAND INFORMATION

Brand name

AndroForte 5

Active ingredient

Testosterone

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Androforte 5.

WHAT IS IN THIS LEAFLET

This leaflet answers some common questions about ANDROFORTE 5. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you using this medicine against the benefits they expect it will have for you.

If you have any concerns about using this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

WHAT ANDROFORTE 5 IS USED FOR

ANDROFORTE 5 is used to replace the body’s natural hormone testosterone when not enough is made by the body.

Testosterone is a natural hormone, known as an androgen, which controls normal sexual development and function in men.

Testosterone is essential for the development and maintenance of the male reproductive organs as well as other male characteristics, such as facial and body hair growth, deep voice, sexual drive, muscle mass and body fat distribution.

ANDROFORTE 5 is a testosterone containing cream that is applied by the patient daily to the skin. The testosterone passes from the cream through the skin and into the bloodstream. Absorption can be variable between individuals.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed it for another reason.

BEFORE YOU USE ANDROFORTE 5

When you must not use it

Do not use ANDROFORTE 5 if you have an allergy to:

  • testosterone, the active ingredient in ANDROFORTE 5
  • any of the ingredients listed at the end of this leaflet.

Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin.

Do not use ANDROFORTE 5 if you have or are suspected to have:

  • prostate cancer
  • breast cancer (a rare condition in men).

ANDROFORTE 5 must not be used by children. The safety of ANDROFORTE 5 in children under 18 years of age has not been established.

ANDROFORTE 5 must not be used by women, particularly if they are or anticipate becoming pregnant. ANDROFORTE 5 may cause harm to the unborn child when administered to pregnant women. ANDROFORTE 5 may cause serious reactions in nursing infants. Pregnant women must avoid any contact with the ANDROFORTE 5 treated skin.

Do not take this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering. If it has expired or is damaged, return it to your pharmacist for disposal.

If you are not sure whether you should start using this medicine, talk to your doctor.

Before you start to use it

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

Tell your doctor if you have, or have had, any of the following medical conditions:

  • high blood calcium levels associated with bone cancer and tumours (hypercalcaemia)
  • high levels of calcium in the urine (hypercalciuria)
  • high blood pressure or heart disease
  • a tendency to retain fluid (signs may include swollen feet or ankles)
  • liver or kidney disease
  • epilepsy (fits)
  • migraines
  • diabetes
  • difficulty in passing water (urinating) due to enlarged prostate gland
  • abnormal pauses in breathing during sleep (sleep apnoea).

ANDROFORTE 5 may quicken the growth of existing prostatic tumours and benign prostatic hyperplasia (enlargement of the prostate gland). It may also increase the risk of breast cancer in males. Before treatment, your doctor should conduct tests to check that you do not have existing prostate or breast cancer. During treatment, your doctor may monitor the effects of this medicine.

Worsening of breathing problems during sleep has been reported during treatment with testosterone replacement in people prone to breathing problems during sleep. This is especially true if you are overweight or have lung problems.

If you use ANDROFORTE 5 over long periods of time, you may develop an abnormal increase in the number of red blood cells in the blood (polycythaemia). Your doctor may organise regular blood counts to monitor this.

If you have not told your doctor about any of the above, tell them before you start using ANDROFORTE 5.

Athletes should note that the active substance, testosterone, may produce a positive reaction in antidoping tests. Misuse of androgens to enhance your physical ability in sport carries serious health risks and is discouraged.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and ANDROFORTE 5 may interfere with each other. These include:

  • oral anticoagulants, medicines used to thin blood and to treat or prevent blood clots
  • corticosteroids or adrenocorticotropic hormone (ACTH), hormones used to control inflammation
  • oxyphenbutazone, a medicine used to treat pain and inflammation
  • insulin, a medicine used to control blood sugar levels
  • bupropion, a medicine used to aid in smoking cessation
  • ciclosporin, a medicine used to suppress the immune system
  • some herbal products such as ancreamica dahurica, chapparal, comfrey, eucalyptus, germander tea, Jin Bu Huan, kava, penny royal oil, skullcap, and valerian.

These medicines may be affected by ANDROFORTE 5 or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while using this medicine.

HOW TO USE ANDROFORTE 5

Follow all directions given to you by your doctor or pharmacist carefully. They may differ from the information contained in this leaflet.

If you do not understand the instructions, ask your doctor or pharmacist for help.

How much to use

Your doctor or pharmacist will explain how and where on the body to apply ANDROFORTE 5.

It is very important to use the correct dose of cream on the correct part of the body because the two sites of application absorb testosterone very differently.

Application to the upper body
The usual starting dose is 2 mL of cream by measured applicator per day applied to the upper body (torso, abdomen and sides of the body). Your doctor or pharmacist will tell you exactly how much to use. You should not use more than 4 mL (200 mg testosterone) of cream per day. The dose should not be varied unless directed to do so by your doctor. You will need to return to your doctor at regular intervals so that the dose can be checked via a blood test.

Application to the scrotum
The usual starting dose is 0.5 mL of cream by measured applicator per day applied to the entire scrotum (the skin sack that holds the testicles). Your doctor or pharmacist will tell you exactly how much to use. You should not use more than 1 mL (50 mg testosterone) of cream per day. The dose should not be varied unless directed to do so by your doctor. You will need to return to your doctor at regular intervals so that the dose can be checked via a blood test.

How to use it

Follow these steps when applying ANDROFORTE 5:

To open the tube, remove the cap and peel off the foil seal. A measuring applicator (syringe style) in a sealed sleeve is enclosed in the ANDROFORTE 5 box. The applicator is marked with 0.25 mL graduations for dosing accuracy.

To measure the correct dose of cream, gently squeeze the base of the ANDROFORTE 5 tube until cream reaches the open nozzle of the tube. Insert the tip of the applicator into the open nozzle of ANDROFORTE 5 cream so that the nozzle and the shoulder of the applicator are in contact. Invert the tube and the applicator so the cream will flow with gravity when squeezed.

Carefully squeeze the base of the ANDROFORTE 5 tube and at the same time slowly withdraw the plunger of the applicator. The cream will flow into the barrel of the applicator.

Do not try to squeeze the cream into the syringe.

Fill the applicator to the required dose. For example: a 2 mL dose of ANDROFORTE 5 (100 mg testosterone) needs the flat part of the plunger level with the 2 mL mark. If there are any air bubbles in the measured dose fill slightly past the required dose mark then depress the plunger so that the excess cream flows back into the tube. Stop at the required dose mark.

To view a demonstration video of how to use the dose application see https://www.lawleypharm.com.au/patients.php

Remove the applicator from the nozzle of the tube and replace the cap firmly on the tube. Depress the plunger of the applicator containing the dose of ANDROFORTE 5 directly onto clean, dry and healthy skin on the part of the body as directed by your doctor:

  • on the upper body including the torso, abdomen and the sides of the body from the waist to just below the arm pits. It is preferable to apply to areas on the upper body with minimal hair and body fat.
  • on the scrotum (the skin sack that holds the testicles). The scrotum does not need to be shaved prior to application of the cream.

Massage the cream into the area until absorbed. Typically, this takes 30 seconds or so. Rinse the applicator in hot water after use and replace in box with ANDROFORTE 5 cream ready for the next day's application.

Wash your hands thoroughly with soap and water after applying the cream.

Cover the application area with clothing once applied.

Do not shower or swim for at least six (6) hours after applying the cream to the upper body or two (2) hours after applying the cream to the scrotum.

When to use it

Apply ANDROFORTE 5 once per day at approximately the same time each day, preferably in the morning. Using it at the same time each day helps maintain a steady level of testosterone in the blood. It will also help you remember when to apply it.

How long to use it

ANDROFORTE 5 helps control the symptoms of your condition, but does not cure it. Therefore you must use ANDROFORTE 5 every day.

When you have finished a tube, start the next tube on the following day. Never leave a break between tubes.

Continue using ANDROFORTE 5 for as long as your doctor tells you to.

If you forget to use it

If you forget to apply a dose, apply it as soon as you remember.

If you do not remember to apply the dose until the next dose is due, then just apply one dose.

Do not apply a double dose to make up for a forgotten individual dose.

Continue as normal the following day.

If you use too much (overdose)

Wash the skin with soap and water.

Immediately telephone your doctor or the Poisons Information Centre on 13 11 26 for advice, or go to Accident and Emergency at the nearest hospital, if you think that you or anyone else may have used too much ANDROFORTE 5. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

WHILE YOU ARE USING ANDROFORTE 5

Things you must do

If you are about to be started on any new medicine, remind your doctor and pharmacist that you are using ANDROFORTE 5.

Tell any other doctors, dentists, and pharmacists who treat you that you are using this medicine.

Keep all of your doctor’s appointments so that your progress can be checked. Your doctor may monitor your blood pressure, examine your prostate and conduct other tests (including blood tests) from time to time, particularly if you are elderly. This is to make sure the medicine is working and to check for unwanted side effects.

The use of ANDROFORTE 5 may affect the results of certain laboratory tests. If you are about to have any tests, tell your doctor that you are using this medicine.

Things you must not do

Do not use ANDROFORTE 5 to treat any other complaints unless your doctor tells you to.

Do not give ANDROFORTE 5 to anyone else, even if they have the same condition as you.

Do not stop using ANDROFORTE 5, or change the dosage, without checking first with your doctor. If you stop using it suddenly, your condition may worsen or you may have unwanted side effects.

Things to be careful of

Testosterone may be transferred to another person during close and relatively prolonged skin contact with the cream application area. If contact occurs a number of times or for long periods of time this could cause the other person to show signs of increased testosterone such as more hair on the face and body and a deepened voice. In women, this may also cause changes in the menstrual cycle. Signs of increased testosterone in children include enlarged penis or clitoris, early development of pubic hair, increased erections or sex drive, aggressive behaviour.

Call your doctor right away if you see any signs in a child or a woman that may have occurred through accidental exposure to ANDROFORTE 5.

Unwanted transfer of testosterone to another person can be avoided by wearing clothes which cover the application area and/or by showering before contact. You need to ensure that your partner is not put at risk of receiving testosterone by accident.

You should leave a gap of 6 hours between applying ANDROFORTE 5 to the upper body and having intimate physical contact. You should also wear clothing such as a T-shirt to cover the application area and/or have a shower or bath beforehand.

If applying ANDROFORTE 5 to the scrotum leave a gap of at least 2 hours after application before intimate contact and/or have a shower or bath beforehand.

If your partner is pregnant, it is extra important that you take care to protect her from testosterone.

If a woman or child does come into contact with ANDROFORTE 5, thoroughly wash the area of skin exposed to the cream with soap and water immediately.

SIDE EFFECTS

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using ANDROFORTE 5.

All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

Do not be alarmed by the list of possible side effects. You may not experience any of them.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor if you notice any of the following and they worry you:

  • skin reactions such as irritation, redness, dry or stinging skin, acne and/or hives, oily skin
  • headaches or migraines
  • prostatic disorders such as difficulty or pain while urinating, frequent urination
  • changes in sexual drive
  • painful, tender or enlarged breasts
  • dizziness, difficulty in breathing or worsening of sleep apnoea
  • increased feeling or sensitivity of skin
  • memory loss
  • changes in the sense of smell or taste
  • mood changes, nervousness, anger
  • increased or decreased blood pressure, flushing
  • increased appetite
  • hair loss, discoloured hair, excessive hairiness
  • muscle cramps or pain
  • unusual weakness, generally feeling unwell
  • changes in the levels of blood glucose.

These are the possible side effects of ANDROFORTE 5.

Tell your doctor immediately, or go to Accident and Emergency department at your nearest hospital if you notice any yellowing of the skin and eyes, also called jaundice. This is a very serious side effect. You may need urgent medical attention or hospitalisation.

Your doctor may need to monitor your blood pressure and conduct blood tests, as ANDROFORTE 5 may increase your blood pressure and affect your liver function. You may not experience any specific symptoms.

Side effects associated with high doses or long-term treatment include:

  • increased tendency to retain fluid (signs may include swollen feet or ankles) and changes in electrolytes
  • decreased sperm count, which may affect fertility
  • reduction in the size of the testicles
  • unwanted, frequent or prolonged and painful erections.

Tell your doctor if you notice anything else that is making you feel unwell.

Other side effects not listed above may also occur in some patients. Some of these side effects can only be found when your doctor does tests from time to time to check your progress:

  • increases in blood cholesterol, increased haematocrit (percentage of red blood cells in the blood), haemoglobin and red blood cell count
  • increased creatinine
  • increased Prostate Specific Antigen (PSA). PSA is a protein produced by the prostate which can be used to detect prostate disease.

AFTER USING ANDROFORTE 5

Storage

Keep ANDROFORTE 5 in a cool dry place where the temperature stays below 25°C.

Do not store it or any other medicine in the bathroom, near a sink, or on a window-sill.

Do not leave it in the car. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and a half metres above the ground is a good place to store medicines.

Disposal

If your doctor tells you to stop using this medicine or the expiry date has passed, ask your pharmacist what to do with any medicine that is left over. Return any unused medicine to your pharmacist.

PRODUCT DESCRIPTION

What it looks like

ANDROFORTE 5 is a white, opaque cream presented in a boxed laminated tube together with a sealed syringe-style measuring applicator marked in 0.5 mL graduations.

ANDROFORTE 5 is supplied in a 50 mL sealed tube.

Ingredients

Active ingredient per tube:

  • ANDROFORTE 5 – 50 mg testosterone per 1 mL of cream

Inactive ingredients:

  • dl-α-tocopheryl acetate (Vitamin E acetate)
  • almond oil
  • cetomacrogol 1000
  • cetostearyl alcohol
  • carbomer 940
  • trolamine
  • butylated hydroxytoluene
  • Phenonip (PI 10352) contains hydroxybenzoates
  • citric acid
  • purified water.

PRESENTATION AND STORAGE CONDITIONS

ANDROFORTE 5 is presented as single boxed tube with a graduated syringe-style measuring device.

ANDROFORTE 5 is supplied in a 50mL sealed tube and contains 50mg testosterone per 1mL of cream.

The tube should not be opened until immediately prior to application of the cream.

Store below 25°C. Do not freeze.

In-use storage: ANDROFORTE 5 should be used within 12 weeks of opening.

Shelf Life: ANDROFORTE 5 has a 36 month shelf-life from the date of manufacture.

For the expiry date and batch number please see the crimp of the tube.

Supplier

Made in Australia for:

Lawley Pharmaceuticals Pty Ltd
Unit 2/15A Harrogate Street
West Leederville WA 6007

ABN 12095973523

Australian Registration Numbers

ANDROFORTE 5 - AUST R 123764

This leaflet was revised in November 2020.

See TGA website (www.tga.gov.au) for latest Australian Consumer Medicine Information.

® Registered Trademark of Lawley Pharmaceuticals Pty Ltd
© Lawley Pharmaceuticals Pty Ltd
All rights reserved.

Published by MIMS February 2021

BRAND INFORMATION

Brand name

AndroForte 5

Active ingredient

Testosterone

Schedule

S4

 

1 Name of Medicine

Testosterone.

2 Qualitative and Quantitative Composition

AndroForte 5 contains 5% w/v testosterone (50 mg in 1 mL or 100 mg in 2 mL).
Contains tree nut products (almond oil) and hydroxybenzoates.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Cream.
AndroForte 5 is a white, opaque, oil-in-water cream.

4 Clinical Particulars

4.1 Therapeutic Indications

AndroForte 5 is indicated for use as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

4.2 Dose and Method of Administration

Adult men (18 years old and above).

Application to the scrotum.

The recommended starting dose of AndroForte 5 when applied to the entire scrotum is 0.5 mL of cream (i.e. 25 mg of testosterone) applied once daily at about the same time, preferably in the morning. The daily dose should be adjusted by the doctor depending on the clinical and/or laboratory response in individual patients, not exceeding 1 mL of cream per day. The adjustment of dosage should be achieved by 0.25 mL increments.
The application should be administered by the patient himself, onto clean, dry, healthy skin on the scrotum. The scrotum is not required to be shaved prior to application.

Application to the upper body.

The recommended starting dose of AndroForte 5 when applied to the upper body is 2 mL of cream (i.e. 100 mg of testosterone) applied once daily at about the same time, preferably in the morning. The daily dose should be adjusted by the doctor depending on the clinical and/or laboratory response in individual patients, not exceeding 4 mL of cream per day. The adjustment of dosage should be achieved by 1 mL increments.
The application should be administered by the patient himself, onto clean, dry, healthy skin to the torso. The torso includes the abdomen and the sides of the body from the waist to just below the armpits. It is preferable to apply to areas with minimal hair and body fat.

Method of administration.

After opening the tube, the patient should be directed to measure the appropriate dose using the graduated applicator and immediately apply to clean dry skin. The cream should be spread on the skin gently and massaged in until vanished. Typically, this takes 30 seconds or so. Wash hands with soap and water after applications. To clean the applicator after use, rinse in hot water.

Monitoring.

Hypogonadal symptom control is the primary aim of testosterone therapy via achieving a serum testosterone concentration sufficient to restore physiological androgen status to that comparable with eugonadal men. Biochemistry is an adjunct indicator of treatment response together with the identification and monitoring of the man's leading symptom. Trough testosterone levels should be within the lower limit of the reference interval for eugonadal men.

Application to the scrotum.

Eugonadal serum testosterone concentrations are generally reached within 24 hours of a single dose of AndroForte 5 applied scrotally. Absorption is variable between individuals and will have a different pharmacokinetic profile for men changing from non-scrotal testosterone products. In order to adjust the testosterone dose for scrotal application it is recommended that two (2) serum testosterone concentrations be measured at 3 hours (peak) and 24 hours (trough) from prior application after the 15th day of starting treatment. Results of clinical and/or biochemical monitoring may prompt dose titration.

Application to the upper body.

Eugonadal serum testosterone concentrations are generally reached within 24 hours of a single dose of AndroForte 5. Absorption is variable between individuals. In order to adjust the testosterone dose, serum testosterone concentrations must be measured in the morning before application after the 15th day of starting treatment. Results of clinical and/or biochemical monitoring may prompt dose titration.

Paediatric use.

AndroForte 5 is not indicated for use in children and has not been evaluated clinically in males under 18 years of age.

4.3 Contraindications

Testosterone is contraindicated in men with known or suspected carcinoma of the breast or prostate.
Hypersensitivity to the active substance (testosterone) or to any of the excipients.

4.4 Special Warnings and Precautions for Use

Androgens may accelerate the progression of subclinical prostate cancer and benign prostatic hyperplasia.
AndroForte 5 should not be used by women or children due to possible virilising effects.
Prior to testosterone initiation, all patients must undergo a detailed examination in order to assess for pre-existing prostate cancer. Careful and regular monitoring of the prostate gland (digital rectal examination and estimation of serum PSA (prostate specific antigen)) and breast must be performed in accordance with recommended practice in patients receiving testosterone therapy at least once yearly and twice yearly in elderly and at risk patients (those with clinical or familial risk factors).
Testosterone should be used only if hypogonadism (hyper- and hypogonadotropic) has been demonstrated and if other aetiology, responsible for the symptoms, has been excluded before treatment is started. Testosterone insufficiency should be clearly demonstrated by clinical features (regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido, erectile dysfunction etc.) and confirmed by two separate blood testosterone measurements. Due to variability in laboratory values, all measures of testosterone should be carried out in the same laboratory.
Testosterone concentrations should be monitored when switching the patient from another testosterone product to AndroForte 5 or when switching from AndroForte 5 upper body application to scrotal application and vice versa.
Modest elevations of serum dihydrotestosterone (DHT) concentrations are commonly observed after scrotal and non-scrotal administration of testosterone, however there is no evidence to suggest that high circulating DHT concentrations have a deleterious effect on the prostate and cardiovascular safety profile.
In addition to monitoring the testosterone concentrations in patients on long-term androgen therapy the following laboratory parameters should be checked periodically: haemoglobin, haematocrit (to avoid the risk of polycythaemia), liver function tests, and lipid profile.
Increases in haematocrit may require reductions in dose or discontinuation of testosterone therapy. Increased haematocrit may increase the risk for a thromboembolic event. Changes in serum lipid profile may require dose adjustment or discontinuation of testosterone therapy.

Clotting disorders.

Testosterone should be used with caution in patients with thrombophilia or risk factors for venous thromboembolism (VTE), as there have been post-marketing studies and reports of thrombotic events (e.g. deep-vein thrombosis, pulmonary embolism, ocular thrombosis) in these patients during testosterone therapy. In thrombophilic patients, VTE cases have been reported even under anticoagulation treatment, therefore continuing testosterone treatment after first thrombotic event should be carefully evaluated. In case of treatment continuation, further measures should be taken to minimise the individual VTE risk.
With specific reference to AndroForte 5, erythrocytosis and skin reactions are at the lowest end of the risk scale when transdermal testosterone is the mode of delivery. If the patient develops a severe application site reaction, treatment should be assessed and discontinued if necessary.
Testosterone is not a treatment for male sterility or impotence in men with normal serum testosterone levels.
With large doses of exogenous androgens, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH) which could possibly lead to adverse effects on semen parameters including sperm count.
Certain clinical signs: irritability, nervousness, weight gain, prolonged or frequent erections may indicate excessive androgen exposure requiring dosage adjustment.
In patients suffering from severe cardiac, hepatic or renal insufficiency or ischemic heart disease, treatment with testosterone may cause severe complications characterised by oedema with or without congestive cardiac failure. In such case, treatment must be stopped immediately. There are no studies undertaken to demonstrate the efficacy and safety of AndroForte 5 in patients with renal or hepatic impairment.
Patients with pre-existing cardiac, hepatic or renal diseases need to be monitored closely when undergoing androgen treatment. Because AndroForte 5 is not taken orally hepatotoxicity is not a risk factor.
Gynecomastia occasionally develops and occasionally persists in patients being treated with androgens for hypogonadism.
There are published reports of increased risk of sleep apnoea in hypogonadal men treated with testosterone, especially those with risk factors such as obesity or chronic lung disease.
Testosterone should be used with caution in patients with epilepsy and migraine as these conditions may be aggravated.
Testosterone should be used with caution in cancer patients at risk of hypercalcaemia (and associated hypercalciuria), due to bone metastases. Regular monitoring of serum calcium concentrations is recommended in these patients.
Testosterone may cause an increase in blood pressure and should be used with caution in patients with hypertension.
Changes in insulin sensitivity may occur in patients treated with androgens who achieve normal testosterone plasma concentrations following replacement therapy.
Athletes should be informed that AndroForte 5 contains an active substance (testosterone), which may give positive results in an antidoping test.
Androgens are not indicated for enhancing muscular development in healthy individuals.

Potential for transfer.

Transdermal testosterone cream can be transferred to other persons by close skin to skin contact, resulting in increased testosterone serum levels and, with repeated contact, possibly adverse effects. In women, this may cause growth of facial and/or body hair, deepening of the voice, irregularities of the menstrual cycle; in children this may cause premature puberty and genital enlargement, in case of repeat contact (inadvertent androgenisation). If virilisation occurs, testosterone therapy should be promptly discontinued until the cause has been identified.
The physician should inform the patient carefully about the risk of testosterone transfer and about safety instructions (see below). AndroForte 5 should not be prescribed to patients with a major risk of noncompliance with safety instructions (e.g. severe alcoholism, drug abuse and severe psychiatric disorders).
The risk of transfer is substantially reduced by wearing clothes covering the application area. The majority of residual testosterone is removed from the skin surface by washing with soap and water prior to contact.
As a result, the following precautions are recommended:

For the patient.

Wash hands thoroughly with soap and water after applying the cream.
Cover the application area with clothing once the cream has dried.
Wash before any situation in which skin-to-skin contact is foreseen.

For people not being treated with AndroForte 5.

In the event of contact with an application area which has not been washed or is not covered with clothing, wash the area of skin onto which testosterone may have been transferred as soon as possible, using soap and water.
Report the development of signs of excessive androgen exposure such as acne or hair modification.
To improve partner safety the patient should be advised to wear a T-shirt covering the upper body application site during the contact period or to shower before sexual intercourse.
To improve partner safety using scrotal application wash the genital area with a damp warm flannel before sexual intercourse.
Furthermore, it is recommended to wear clothing covering the upper body application site during contact periods with children in order to avoid transference to children.
Pregnant women must avoid any contact with AndroForte 5 application sites. In case of pregnancy of the partner, the patient must be particularly careful to avoid potential transfer.

Use in hepatic impairment.

No formal studies were conducted with AndroForte 5 involving patients with hepatic impairment. Lower doses may be required in hepatic impairment.

Use in renal impairment.

No formal studies were conducted with AndroForte 5 involving patients with renal impairment. Lower doses may be required in renal impairment.

Use in the elderly.

There is limited experience of the use of testosterone in elderly patients over 65 years of age. Currently, there is no consensus about age specific testosterone reference values. However, it should be taken into account that physiological testosterone serum levels are lower with increasing age.

Paediatric use.

The safety and efficacy of AndroForte 5 in children and adolescents aged under 18 years of age has not been established.
The patient should be advised to wash their hands well with soap and water after AndroForte 5 has been applied in case of contact with children.

Effects on laboratory tests.

Androgens may decrease levels of thyroxine binding globulin resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Changes in insulin sensitivity, glucose tolerance, glycaemic control, blood glucose and glycosylated haemoglobin have been reported with androgens. In diabetic patients, medication requirements may change.
When androgens are used simultaneously with anticoagulants, the anticoagulant effects may be increased. More frequent monitoring of INR and prothrombin time is recommended in patients taking anticoagulants, especially at the initiation and termination of androgen therapy.
The concurrent use of testosterone with ACTH or corticosteroids may result in increased fluid retention and should be monitored, particularly in patients with cardiac, renal or hepatic disease.
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
In diabetic patients, the metabolic effects of androgens may decrease blood glucose levels, and therefore, insulin requirements.
Concurrent administration of testosterone and bupropion may result in a lowered seizure threshold.
Concurrent administration with ciclosporin may result in increased ciclosporin toxicity and elevated ciclosporin blood levels.
Theoretically, in general, any substance which affects liver function should not be taken with testosterone, although this may not be as problematic with transdermal preparations such as AndroForte 5. Examples of herbal products include: ancreamica dahurica, chapparal, comfrey, eucalyptus, germander tea, Jin Bu Huan, kava, penny royal oil, skullcap, and valerian.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Fertility studies in rodents and primates have shown that treatment with testosterone can impair fertility by suppressing spermatogenesis in a dose dependent manner.
(Category D)
Testosterone is contraindicated in women who are or who anticipate becoming pregnant. Pregnant women must avoid any contact with AndroForte 5 application sites. Exposure of a fetus to androgens may result in varying degrees of virilisation. In the event of contact, women are advised to wash with soap and water as soon as possible.
Testosterone should not be used by breastfeeding women. In the event of accidental contact, women are advised to immediately wash with soap and water.

4.7 Effects on Ability to Drive and Use Machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8 Adverse Effects (Undesirable Effects)

According to the literature or post-marketing reports or studies, additional undesirable events that are possibly or probably related to testosterone use are shown in Table 1.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).
No cases of overdose with AndroForte 5 have been reported in clinical trials.
Treatment of overdose would consist of discontinuation of AndroForte 5 together with appropriate symptomatic and supportive care. Wash the skin with soap and water.

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

AndroForte 5 is an androgen replacement therapy containing the male hormone testosterone.
Endogenous androgens, principally testosterone, secreted by the testes and its major metabolite dihydrotestosterone (DHT), are responsible for the development of the external and internal genital organs and for maintaining the secondary sexual characteristics (stimulating hair growth, deepening of the voice, development of the libido); for a general effect on protein anabolism; for development of skeletal muscle and body fat distribution; for a reduction in urinary nitrogen, sodium, potassium, chloride, phosphate and water excretion.
Testosterone does not produce testicular development: it reduces the pituitary secretion of gonadotropins.
The effects of testosterone in some target organs arise after peripheral conversion of testosterone to oestradiol, which binds to oestrogen receptors in the target cell nucleus e.g. the pituitary, fat, brain, bone and testicular Leydig cells.

Clinical trials.

Application to upper body.

The pivotal study was a phase II, randomised, crossover bioequivalence study of AndroForte 5 and a commercially available nonscrotal 1% transdermal testosterone gel (Testogel). Hypogonadal men (N = 15) were assigned to receive 2 mL AndroForte 5 (100 mg testosterone) per day, or 50 mg testosterone gel (5 mL of a 1% gel) per day for 30 days. The primary efficacy analysis was designed to demonstrate the bioequivalence of AndroForte 5 with the 1% testosterone gel on the basis of AUC and Cavg serum testosterone levels being within the eugonadal range. Other efficacy variables that were examined included: testosterone concentrations at day 30, dihydrotestosterone, oestradiol, luteinising hormone, follicle stimulating hormone and steroid hormone binding globulin concentrations, sexual questionnaire, mood/ energy questionnaire, general health survey and erectile function questionnaire. AndroForte 5 was bioequivalent to Testogel for the key pharmacokinetic parameters of Cmax, Cavg and AUC using adjusted and unadjusted for baseline values.
Table 2 demonstrates the Cmax and Cavg serum testosterone levels (nanomol/L) achieved from baseline up to 30 days of treatment in hypogonadal men from the pivotal phase II comparator trial in the same hypogonadal subjects.

Application to the scrotum.

A three-phase single-dose cross-over pharmacokinetic study of AndroForte 5 in endogenous testosterone suppressed healthy volunteers (n=11) described by Iyer 20171 demonstrated a nonlinear dose-dependent increase in serum testosterone Cmax following scrotal administration of testosterone doses of 12.5 mg, 25 mg and 50 mg. Testosterone was rapidly absorbed from the scrotal skin with a mean Tmax of 3.3-5.3 h. The mean Cmax (± SEM) for the 12.5 mg, 25 mg and 50 mg testosterone doses was 19.8 ± 3.8, 21.9 ± 2.8 and 28.8 ± 3.8 nanomol/L, respectively. Serum testosterone concentrations were maintained within the physiological reference range of 1.8-7.8 nanogram/mL (6.2-26.9 nanomol/L) for at least 12 h at the lowest 12.5 mg dose and for over 16 h for the 25 mg and 50 mg dose levels. Serum DHT concentrations after scrotal testosterone administration were higher than the physiological reference range of 0.07-0.64 nanogram/mL (0.24-2.21 nanomol/L) and independent of dose with a mean Cmax of 4.5-4.9 nanomol/L. Serum estradiol concentrations were independent of testosterone dose and remained within the physiological range of 15-68 picogram/mL (55-250 picomol/L) for 16 h post-dose. AndroForte 5 cream was well tolerated when applied to the scrotum with no complaints of skin irritation or discomfort after application. See Figure 1.
1 Iyer R, Mok SF, Savkovic S, et al. Pharmacokinetics of testosterone cream applied to scrotal skin. Andrology. 2017 Jul;5(4):725-731.

5.2 Pharmacokinetic Properties

Absorption.

Following percutaneous absorption, testosterone diffuses into the systemic circulation at relatively constant concentrations during the 24 hour cycle.
Serum testosterone concentrations increase from the first hour after an application of AndroForte 5, reaching eugonadal levels within 24 hours. Daily changes in testosterone concentrations are then of similar amplitude to those observed during the circadian rhythm of endogenous testosterone. The percutaneous route avoids blood peaks or the first pass effect of oral androgen therapy.
Administration of 2 mL of AndroForte 5 (100 mg testosterone) to the torso produces an average testosterone concentration increase in hypogonadic men of approximately 7.7 nanomol/L in serum with a Tmax around 14.8 hours after application.
Administration of a single dose 0.5 mL of AndroForte 5 (25 mg testosterone) to the scrotum of healthy eugonadal volunteers with endogenous testosterone suppressed by administration of nandrolone decanoate produced a Cmax serum testosterone concentration of 19.1 nanomol/L with a Tmax around 2.8 hours after application.
The half-life of testosterone is controlled by skin permeation and not clearance/ metabolism.

Metabolism.

The major active metabolites of testosterone are DHT and oestradiol.

Excretion.

Testosterone is excreted, mostly in urine, and in faeces as conjugated testosterone metabolites.

5.3 Preclinical Safety Data

Genotoxicity.

The genotoxic potential of testosterone has not been fully investigated in a comprehensive battery of genotoxicity studies. However, testosterone was found not to be clastogenic when tested in vitro in assays with hamster lung fibroblasts or in mouse or hamster embryo fibroblasts, or in in vivo chromosome aberration assays in mouse bone marrow cells and spermatocytes. Testosterone was also negative in assays for unscheduled DNA synthesis in rat and human hepatocytes.

Carcinogenicity.

A relationship between androgen treatment and certain cancers has been found in laboratory animals. Experimental data in rats have shown increased incidences of prostate cancer after treatment with testosterone.
Sex hormones are known to promote the growth of certain hormone dependent tissues and tumours. Subcutaneous implantation of testosterone produced cervical-uterine tumours in female mice, which metastasised in some cases. Metastasising prostatic adenocarcinomas occurred in male rats after chemical induction and subcutaneous implantation of testosterone. Testosterone is also known to increase the number of tumours and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats. Hepatocellular carcinoma has been reported in patients receiving long-term therapy with androgens.
Hypogonadal men receiving androgen replacement therapy require surveillance for prostatic disease similar to that recommended for eugonadal men of comparable age.

6 Pharmaceutical Particulars

6.1 List of Excipients

Almond oil, butyl hydroxybenzoate, butylated hydroxytoluene, carbomer 940, cetomacrogol 1000, cetostearyl alcohol, citric acid, dl-alpha-tocopherol acetate, ethyl hydroxybenzoate, isobutyl hydroxybenzoate, methyl hydroxybenzoate, phenoxyethanol, propyl hydroxybenzoate, purified water, trolamine.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

The tube should not be opened until immediately prior to application of the cream.
Store below 25°C. Do not freeze.
In-use storage: AndroForte 5 should be used within 125 days of opening.

6.5 Nature and Contents of Container

AndroForte 5 is supplied in a 50 mL sealed tube with a dose applicator marked with 0.25 mL graduations in a carton.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Chemical structure.

Testosterone is an androgen. Chemically, testosterone is 17β-hydroxyandrost- 4-en-3-one and has the following structural formula:
Chemical Formula: C19H28O2.
Molecular Weight: 288.4 g/mol.
Testosterone is a white, crystalline powder, odourless or almost odourless produced semisynthetically from plant origin. It is practically insoluble in water, freely soluble in ethanol (96%); slightly soluble in ethyl oleate.

CAS number.

58-22-0.

7 Medicine Schedule (Poisons Standard)

S4 Prescription Only Medicine.

Summary Table of Changes